GlaxoSmithKline plc

(the 'Company')

Transfer of Treasury Shares

On 10 February 2022, the Company transferred 50,300,000 ordinary shares of 25 pence each ("Ordinary Shares") that were held by the Company in treasury ("Treasury Shares") of which (a) 34,500,000 Ordinary Shares were transferred to the Company's Jersey resident trust, the GlaxoSmithKline Employee Trust (the "Jersey Trust"), and (b) 15,800,000 Ordinary Shares were transferred to JPMorgan Chase Bank, N.A. the depositary of the Company's American depositary receipts ("ADR") programme, to procure the issuance and transfer of  7,900,000 ADRs of the Company to the GlaxoSmithKline (US) Trust (the "US Trust"), such Ordinary Shares and those ADRs to be used to satisfy awards granted under the Company's Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee of the Jersey Trust, of £16.208 per Ordinary Share, was funded by a loan from GlaxoSmithKline Services Unlimited, and the consideration received from the trustee of the US Trust of $44.260 per ADR, representing $22.130 per Ordinary Share, was funded by a contribution to the US Trust from GlaxoSmithKline LLC.

Following the transfer and as at 11 February 2022, the Company's issued share capital consisted of 5,388,496,258 Ordinary Shares, of which 304,905,950 were held as Treasury Shares.

Therefore, the total number of voting rights in the Company is 5,083,590,308. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

V A Whyte

Company Secretary

14 February 2022